Forgot your password?

Forgot your username?

database > company
Indevus Pharmaceuticals
Biotech Specialty Pharma
33 Hayden Ave
Lexington, MA 02421 USA
phone:(781) 861-8444
fax:(781) 861-3830
Symbol IDEV
Exchange NASDAQ
Founded 0
Employees
www.interneuron.com
Research Sector Biotech Specialty Pharma
Summary Description
The Company has a broad portfolio of drugs in development.
Management
Glenn L. Cooper,M.D, chairman,and chief executive officer; Noah D. Beerman, Executive vice president; Mark S. Butler, Executive vice president, chief administrative officer; Dale Ritter, senior vice president of finance; Michael W. Rogers, Executive vice president,chief financial officer and treasurer; Bobby W. Sandage, Jr., Ph.D., Executive vice president, research and development, and chief scientific officer
Ownership
Financials Mkt Cap :263


* numbers in thousands
 

Keywords
overactive bladder, pagoclone for panic and generalized anxiety disorders, ischemic stroke, inflammatory disorders, HIV, advamed, HIVAIDS

Comment | Printable Version | Modify profile |
Updated: Jan. 22, 2009

Description
Indevus Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diversified portfolio of product candidates, including multiple compounds in late-stage clinical development.
Products / Services
As of September 30, 2003, the Company had six compounds in development: trospium for overactive bladder, pagoclone for panic and generalized anxiety disorders, citicoline for ischemic stroke, IP 751 for pain and inflammatory disorders, PRO 2000 for the prevention of infection by the human immunodeficiency virus and other sexually transmitted pathogens and aminocandin for treatment of systemic fungal infections.
Funding
In addition to its product candidates in development, Indevus is receiving royalties under a patent it licensed to Eli Lilly & Company based on net sales of Sarafem in the United States. Sarafem is prescribed to treat certain conditions and symptoms associated with pre-menstrual syndrome.


2012-02-03-713